<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39434493</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Collaborative Real-World Evidence Among Regulators: Lessons and Perspectives.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpt.3457</ELocationID><Abstract><AbstractText>The International Coalition of Medicines Regulatory Authorities (ICMRA), comprising 38 global medicines regulatory authorities, collaborates on shared challenges, notably during the COVID-19 pandemic. This article focuses on the ICMRA COVID-19 Real-World Evidence (RWE) and Observational Studies Working Group. The Working Group aimed to address challenges related to RWE and observational studies during the pandemic, resulting in impactful studies and ICMRA statements on international collaboration for RWE and COVID-19 vaccine safety. Reflecting on 3 years of collaboration, the Working Group surveyed members for insights, and recommendations were formulated to enhance research preparedness, collaboration, and response to future public health emergencies. The lessons learned highlight the importance of global collaborations, governance structures for rapid decision-making, and effective utilization of existing networks. Recommendations include the establishment of an international governance structure, a "coalition of the willing" for swift research collaboration, dedicated sub-groups, periodic workshops, common protocols, joint timelines, and data model templates, leveraging existing infrastructure, and strengthening outreach for transparency and engagement. The Working Group envisions repurposing into an RWE strategic and operational entity, contributing to global public health emergency response mechanisms. In conclusion, the Working Group's success lies in effective communication, collaborative research, and leveraging existing infrastructure, with ongoing contributions to global emergency response mechanisms.</AbstractText><CopyrightInformation>© 2024 His Majesty the King in Right of Canada and The Author(s). Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. Reproduced with the permission of the Minister of Health Canada.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0002-8308-2202</Identifier><AffiliationInfo><Affiliation>Health Canada, Health Products and Food Branch, Marketed Health Products Directorate, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kampman</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Canada, Health Products and Food Branch, Marketed Health Products Directorate, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huynh</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Health Canada, Health Products and Food Branch, Marketed Health Products Directorate, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Health Canada, Health Products and Food Branch, Marketed Health Products Directorate, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plueschke</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1824-4148</Identifier><AffiliationInfo><Affiliation>European Medicines Agency, Data Analytics and Methods Task Force, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohet</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0022-7251</Identifier><AffiliationInfo><Affiliation>European Medicines Agency, Data Analytics and Methods Task Force, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verpillat</LastName><ForeName>Patrice</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0010-1699</Identifier><AffiliationInfo><Affiliation>European Medicines Agency, Data Analytics and Methods Task Force, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Health Canada, Health Products and Food Branch, Marketed Health Products Directorate, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arlett</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6640-0117</Identifier><AffiliationInfo><Affiliation>European Medicines Agency, Data Analytics and Methods Task Force, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>2</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39434493</ArticleId><ArticleId IdType="doi">10.1002/cpt.3457</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>International Coalition of Medicines Regulatory Authorities (ICMRA) &lt;https://icmra.info/drupal/en/aboutus&gt; (2024).</Citation></Reference><Reference><Citation>Covid‐19 infectiON and medicineS In preGNancy (CONSIGN) &lt;https://zenodo.org/communities/consign?q=&amp;l=list&amp;p=1&amp;s=10&amp;sort=newest&gt;.</Citation></Reference><Reference><Citation>COVID‐19: EMA sets up infrastructure for real‐world monitoring of treatments and vaccines (Amsterdam, The Netherlands: European Medicines Agency) &lt;https://www.ema.europa.eu/en/news/covid‐19‐ema‐sets‐infrastructure‐real‐world‐monitoring‐treatments‐and‐vaccines&gt; (2020).</Citation></Reference><Reference><Citation>Hurley, E. et al. COVID‐19 and pregnancy: a European study on pre‐ and post‐infection medication use. Eur J Clin Pharmacol 80, 707–716 (2024).</Citation></Reference><Reference><Citation>Smith, E.R. et al. Clinical risk factors of adverse outcomes among women with COVID‐19 in the pregnancy and postpartum period: a sequential, prospective meta‐analysis. Am J Obstet Gynecol 228, 161–177 (2023).</Citation></Reference><Reference><Citation>Layton, D. Systemic glucocorticoids in the treatment of COVID‐19 and risks of adverse outcomes in COVID‐19 patients in the primary and secondary care setting &lt;https://www.encepp.eu/encepp/viewResource.htm?id=41699&gt; (2020).</Citation></Reference><Reference><Citation>Bradley, M.C. et al. Systemic corticosteroid use for COVID‐19 in US outpatient settings from April 2020 to august 2021. JAMA 327, 2015–2018 (2022).</Citation></Reference><Reference><Citation>Re, V.L. &amp; Cocoros, N. Assessment of the Natural History of Coagulopathy in COVID‐19 | Sentinel Initiative &lt;https://www.sentinelinitiative.org/methods‐data‐tools/methods/assessment‐natural‐history‐coagulopathy‐covid‐19&gt; (2020).</Citation></Reference><Reference><Citation>Lo Re, V. et al. Association of COVID‐19 vs influenza with risk of arterial and venous thrombotic events among hospitalized patients. JAMA 328, 637–651 (2022).</Citation></Reference><Reference><Citation>Lo Re, V. et al. Risk of admission to hospital with arterial or venous thromboembolism among patients diagnosed in the ambulatory setting with covid‐19 compared with influenza: retrospective cohort study. BMJ Med 2, e000421 (2023).</Citation></Reference><Reference><Citation>Prieto‐Alhambra, D. &amp; Burn, E. Natural history of coagulopathy and use of anti‐thrombotic agents in COVID‐19 patients and persons vaccinated against SARS‐CoV‐2 &lt;https://www.encepp.eu/encepp/openAttachment/studyResultLatest/45219&gt; (2021).</Citation></Reference><Reference><Citation>Burn, E. et al. Venous or arterial thrombosis and deaths among COVID‐19 cases: a European network cohort study. Lancet Infect Dis 22, 1142–1152 (2022).</Citation></Reference><Reference><Citation>Li, X. et al. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid‐19 vaccines: international network cohort study from five European countries and the US. BMJ 379, e071594 (2022).</Citation></Reference><Reference><Citation>Lo Re Iii, V. et al. Risk of arterial and venous thrombotic events among patients with COVID‐19: a multi‐National Collaboration of regulatory agencies from Canada, Europe, and United States. Clin Epidemiol 16, 71–89 (2024).</Citation></Reference><Reference><Citation>Kluberg, S.A. et al. Validation of diagnosis codes to identify hospitalized COVID‐19 patients in health care claims data. Pharmacoepidemiol Drug Saf 31, 476–480 (2022).</Citation></Reference><Reference><Citation>International Coalition of Medicines Regulatory Authorities (ICMRA). ICMRA statement on international collaboration to enable real‐world evidence (RWE) for regulatory decision‐making &lt;https://www.icmra.info/drupal/sites/default/files/2022‐07/icmra_statement_on_rwe.pdf&gt; (2022).</Citation></Reference><Reference><Citation>International Coalition of Medicines Regulatory Authorities (ICMRA) &amp; World Health Organization (WHO). Statement for healthcare professionals: How COVID‐19 vaccines are regulated for safety and effectiveness (Revised March 2022) &lt;https://www.who.int/news/item/17‐05‐2022‐statement‐for‐healthcare‐professionals‐how‐covid‐19‐vaccines‐are‐regulated‐for‐safety‐and‐effectiveness&gt; (2022).</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration (FDA). FDA's sentinel initiative (Silver Spring, Maryland, United States: FDA) &lt;https://www.fda.gov/safety/fdas‐sentinel‐initiative&gt; (2023).</Citation></Reference><Reference><Citation>Canadian Network for Observational Drug Effects Studies (CNODES). Canadian Network for Observational Drug Effects Studies &lt;https://www.cnodes.ca/&gt;.</Citation></Reference><Reference><Citation>Suissa, S. et al. CNODES: the Canadian network for observational drug effect studies. Open Med Peer‐Rev Indep Open‐Access J 6, e134–e140 (2012).</Citation></Reference><Reference><Citation>Canadian Agency for Drugs and Technologies in Health (CADTH). Post‐Market Drug Evaluation (PMDE) Program &lt;https://www.cadth.ca/post‐market‐drug‐evaluation‐pmde‐program&gt;.</Citation></Reference><Reference><Citation>Canadian Institutes of Health Research (CIHR). The Drug Safety and Effectiveness Network (DSEN) &lt;https://cihr‐irsc.gc.ca/e/39389.html&gt; (2009).</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Data Analysis and Real World Interrogation Network (DARWIN EU) &lt;https://www.ema.europa.eu/en/about‐us/how‐we‐work/big‐data/data‐analysis‐and‐real‐world‐interrogation‐network‐darwin‐eu&gt;.</Citation></Reference><Reference><Citation>Arlett, P., Kurz, X., Soltys, K. &amp; Blum, M.D. International collaboration in real‐world evidence generation for direct acting Oral anti‐coagulants. Clin Pharmacol Ther 109, 299–301 (2021).</Citation></Reference><Reference><Citation>International Coalition of Medicines Regulatory Authorities (ICMRA). 9th ICMRA Teleconference Minutes COVID‐19 Real‐World Evidence observational studies Working Group &lt;https://icmra.info/drupal/covid‐19/11september2023&gt; (2023).</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Global regulators work towards strengthening collaboration on observational research beyond COVID‐19 pandemic (Amsterdam, The Netherlands: European Medicines Agency) &lt;https://www.ema.europa.eu/en/news/global‐regulators‐work‐towards‐strengthening‐collaboration‐observational‐research‐beyond‐covid‐19‐pandemic&gt; (2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>